SCHEMBL6433018

SCHEMBL6433018

CC(C)(C)OC(=O)CN(Cc1ccccc1)C(=O)c1ccc2c(Cl)cnc(Cl)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.38
CTSS P25774 2/20 0.38
CTSK P43235 1/20 0.38
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PLAU P00749 1/20 0.37
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
LMNA P02545 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
LPAR1 Q92633 1/20 0.36
LPAR5 Q9H1C0 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433655 0.84 ALDH1A1 (0.40) KMT2AMEN1PLAUALDH1A1HTT
SCHEMBL6434696 0.83 NR1D1 (0.43) CTSSKMT2AMEN1L3MBTL1PLAU
SCHEMBL6433131 0.79 PLAU (0.58) CTSSL3MBTL1PLAUCTSLTRPM8
SCHEMBL6434223 0.74 RXRA (0.32) PLAUALDH1A1
SCHEMBL6434389 0.74 PTPRC (0.49) KMT2AMEN1L3MBTL1ALDH1A1MAPK1
SCHEMBL6433083 0.73 PLAU (0.57) KMT2AMEN1L3MBTL1PLAULMNA
SCHEMBL6435282 0.72 ROCK2 (0.53) KMT2AMEN1ALDH1A1NPSR1MAPK1
SCHEMBL6433264 0.72 ROCK2 (0.44)
SCHEMBL6435278 0.72 ROCK2 (0.53) KMT2AMEN1ALDH1A1NPSR1MAPK1
SCHEMBL6433766 0.72 PLAU (0.51) CTSSPLAUCTSLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CFTR 400/4885CTSS 180/4885CTSK 129/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CFTR 400/4885CTSS 180/4885CTSK 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.